|
Gastroenterology / Original Article
Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer
Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim
Korean J Intern Med. 2025;40(1):49-56. Published online January 1, 2025
Background/Aims: Immune checkpoint inhibitors (ICIs) are effective in treating cancer. However, various immune-related adverse events (irAEs) have become prevalent, with ICI-induced colitis being the most common gastrointestinal irAE. Thus, we aimed to investigate the incidence and risk factors of I..
|
|
|
Endocrinology-metabolism / Original Article
Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
Hyunji Sang, Yun Kyung Cho, Sang-hyeok Go, Hwa Jung Kim, Eun Hee Koh
Korean J Intern Med. 2024;39(5):801-812. Published online August 30, 2024
Background/Aims: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events, including endocrine dysfunctions, which can have serious consequences on patient health and quality of life. The clinical course and characteristics of immune-related hypophysitis (irH) are not well establ..
|
|
|
Pulmonology / Review
Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
Jae Kyeom Sim, Juwhan Choi, Sung Yong Lee
Korean J Intern Med. 2023;38(6):787-796. Published online November 1, 2023
Lung cancer is a dismal disease as a leading cause of overall cancer death, but the development of immune checkpoint inhibitors (ICIs) in driver gene mutation negative metastatic non-small cell lung cancer (NSCLC) is changing the paradigm of lung cancer treatment. Recently, ICIs are expanding their ..
|
|
|
Hemato-oncology / Review
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Sung Won Lim, Myung-Ju Ahn
Korean J Intern Med. 2019;34(1):50-59. Published online September 3, 2018
Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). Applications of targeted therapy, such as an epidermal g..
|
|
|
